The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors

Anti-Cancer Drugs

Volumn 15, Issue 2, 2004, Pages 85-106

  Schöffski, Patrick ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Biomodulation; Oral fluoropyrimidine; S 1; Tegafur; TS 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IRINOTECAN; TS 1;

ANEMIA; ANOREXIA; AREA UNDER THE CURVE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NAUSEA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOLID TUMOR; STOMATITIS; STRUCTURE ANALYSIS; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS; OXONIC ACID; PRODRUGS; PYRIDINES; PYRIMIDINES; TEGAFUR;

EID: 1542269125     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Machover D, Rustum YM. Fluoropyrimidines. In: Cvitkovic E, Droz JP, Armand JP, Khoury S (editors): Handbook of Chemotherapy in Clinical Oncology. Jersey: Scientific Communications; 1993, pp. 340-345.
2. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (Capecitabine, UFT, S-1): a review. The Oncologist 2002; 7:288-323.
3. Cunningham D, Coleman R. New options for outpatient chemotherapy - the role of oral fluoropyrimidines. Cancer Treat Rev 2001; 27:211-220.
4. Kubota T. [5-fluorouracil and dihydropyrimidine dehydrogenase]. Gan To Kagaku Ryoho 2001; 28:433-439.
5. Papamichael D. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. The Oncologist 1999; 4:478-487.
6. Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 1999; 5:2289-2296.
7. Iyer L, Ratain MJ. 5-Fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest 1999; 17:494-506.
8. Benson 3rd AB. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results. Oncology (Huntingt) 1998; 12(suppl 7):28-34.
9. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7:425-432.
10. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36:123-128.
11. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
12. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16:3537-3541.
13. Malet-Martino M, Jolimaitre P, Martino R. The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents 2002; 2:267-310.
14. de Bono JS, Twelves CJ. The oral fluorinated pyrimidines. Invest New Drugs 2001; 19:41-59.
15. Hoff PM, Royce M, Medgyesy D, Brito R, Pazdur R. Oral fluoropyrimidines. Semin Oncol 1999; 26:640-646.
16. Tanaka F, Fukuse T, Wada H, Fukushima M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol 2000; 1:137-164.
17. Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40:2223-2228.
18. Schilsky R. Recent advances in oral fluoropyrimidine therapy. Oncology 1998; 12(suppl 7):9-11.
19. Daher GC, Harris BE, Willard EM, Diasio RB. Biochemical basis for circadian-dependent metabolism of fluoropyrimidines. Ann NY Acad Sci 1991; 618:350-361.
20. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995; 14:1-6.
21. McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 1996; 41:425-427.
22. Allegra CJ, Grem JL. Antimetabolites. In: DeVita VT, Hellman S, Rosenberg SA (editors): Cancer Principles and Practice of Oncology, 5th edn. Philadelphia. PA: Lippincott-Raven; 1997, pp. 437-452.
23. Schmoll HJ. Where do we stand with 5-fluorouracil? Semin Oncol 1999; 26:589-605.
24. Shirasaka T, Taguchi T. Preclinical and clinical practice of S-1 in Japan. In: Rustum YM (editor): Fluoropyrimidines in Cancer Therapy. Totowa, NJ: Humana Press; 2003, pp. 285-302.
25. Ignoffo RJ. Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer. Am J Health Syst Pharm 1999; 56:2417-2428.
26. Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs 2000; 18:331-342.
27. Peters GJ, Jansen G. Resistance to antimetabolites. In: Schilsky RL, Milano GA, Ratain MJ (editors): Principles of Antineoplastic Drug Development and Pharmacology. New York: Marcel Dekker; 1996, pp. 543-585.
28. Maehara Y. Comprehensive review of S-1 for gastric cancer. Gastric Cancer 2003; 6(suppl 1):2-8.
29. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5:2000-2005.
30. Ogawa M. Novel anticancer drugs in Japan. J Cancer Res Clin Oncol 1999; 125:134-140.
31. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997; 39:205-211.
32. Matsushima E, Yoshida K, Kitamura R, Yoshida K. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihyroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. Chromatogr Biomed Sci Appl 1997; 691:95-104.
33. Diasio RB. The role of dihydropyrimidine dehydrogenae (DPD) modulation in 5-FU pharmacology. Oncology 1998; 12(suppl 7):23-27.
34. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Tonekura K, et al. Development of a novel form of an oral 5-fuorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
35. Toide H, Akiyoshi H, Minato Y, Okua H, Fujii S. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 1977; 68:553-560.
36. Tatsumi K, Fukushima M, Shirasaka T, Fujji S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78:748-755.
37. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydropyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56:2602-2606.
38. Takechi T, Fujioka A, Matsushima E, Fukushima M. Enhancement of the antiumor activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD) using 5-chloro-2,4-dihydropyrimidine (CDHP) in human tumor cells. Eur J Cancer 2002; 38:1271-1277.
39. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitimor activity in rats. Cancer Res 1993; 53:4004-4009.
40. Kato T, Shimamoto Y, Uchida J, Ohshimo H, Abe M, Shirasaka T, et al. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. Anticancer Res 2001; 21:1705-1712.
41. Yoshisue K, Masuda H, Matsushima E, Ikeda K, Nagayama S, Kawaguchi Y. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab Dispos 2000; 28:1162-1167.
42. Yoshisue K, Hironaga K, Yamaguchi S, Yamamoto A, Nagayama S, Kawaguchi Y. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Cancer Chemother Pharmacol 2000; 46:51-56.
43. Shirasaka T, Fukushima M, Shimamoto Y, Kimura K, et al. Preclinical studies on S-1, a new oral tegafur plus modulators: optimal molar ratio and antitumor activity. Proc Int Congr Chemother 1993; 18:927 (abstr).
44. Konno H, Tanaka T, Baba M, Kawai T, Matsumoto K, Kamiya K, et al. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Jpn J Cancer Res 1999; 90:448-453.
45. Nishimura G, Yanoma S, Mizuno H, Sakate K, Taguchi T, Ikeda Y, et al. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells. Cancer Lett 2000; 159:1-7.
46. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, et al. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 1998; 13:693-698.
47. Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 1998; 9:817-823.
48. Cao S, Lu K, Toth K, Slocum HK, Shirasaka T, Rustum YM, et al. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. Clin Cancer Res 1999; 5:267-274.
49. Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, et al. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-fluorouracil. Oncology 2003; 64:176-182.
50. Shirasaka T, Shimamoto Y, Kato T, Fukushima M. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil]. Gan To Kagaku Ryoho 1998; 25:371-384.
51. Package Insert. TS-1® capsule 20. TS-1® capsule 25. Tegafur, Gimestat and Otastat Potassium Capsule. Revised October 2002.
52. Suzuki M, Seiguchi I, Sato I, Shirasaka T. Combined effects of S-1, a new form of oral tegafur plus moderators in ovarian cancer in nude rats. Chemotherapy 1996; 42:452-458.
53. Kondo K, Akiyama S, Kasai Y, Kato S, Kuno Y, Kataoka M, et al. [Antitumor effect of S-1 and cisplatin treatment against human gastric xenografted in nude mice]. Gan To Kagaku Ryoko 1997; 24:1103-1108.
54. Araki H, Fukushima M, Kamiyama Y, Shirasaka T. Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett 2000; 160:185-191.
55. Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, et al. [Phase I study of S-1. S-1 Study Group.] Gan To Kagaku Ryoho 1997; 24:2253-2264.
56. Hoff PM, Wenske CA, Medgyesy DC, Royce ME, Brito R, Zukowski TH, et al. Phase I and pharmacokinetic (PK) study of a novel oral fluoropyrimidine, S-1. Proc Am Soc Clin Oncol 1999; 18:665 (abstr).
57. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003; 9:134-142.
58. van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18:2772-2779.
59. Meropol NJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, et al. Phase I and pharmacokinetic study of single daily oral administration of S-1. Proc Am Soc Clin Oncol 2001; 20:361 (abstr).
60. Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, et al. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 2002; 8:2116-2122.
61. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimara Y, et al. Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 2003; 89:816-820.
62. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 2002; 50:25-32.
63. Saad ED, Hoff PM. Other fluorinated pyrimidines in the treatment of solid tumors. Oncology (Huntingt) 2001; 15(suppl 2):65-68.
64. Horikoshi N, Mitachi Y, Sakata Y, Sugimachi K, Taguchi T. S-1, new oral fluoropyrimidine is very active in patients with advanced gastric cancer (early phase II study). Proc Am Soc Clin Oncol 1996; 15:466 (abstr).
65. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 1999; 57:202-210.
66. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58:191-197.
67. Kurihara M, Koizumi W, Hasegawa K, Nakano K. Late phase II study of S-1, a novel oral fluoropyrimidine derivative in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1998; 17:1007 (abstr).
68. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
69. Miyamoto S-I, Boku N, Ohtsu A, Yoshida S, Ochiai A, Okabe H, et al. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidines (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol 2000; 17:653-658.
70. Yoshida K, Nishimoto N, Kagawa Y, Hihara J, Inoue H, Kim R, et al. [A new therapeutic approach to advanced and recurrent gastric cancer by TS-1.] Gan To Kagaku Ryoho 2001; 28:1403-1412.
71. Inaba Y, Watabe S, Ohe S, Kamio Y, Koyama M, Hayashi K, et al. [The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho 2002; 29:239-244.
72. Osugi H, Takada N, Takemura M, Kaseno S, Lee S, Ueno M, et al. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination. Oncol Rep 2002; 9:811-815.
73. Moriwaki T, Hyodo I, Nishina T, Kajiwara T, Tsuzuki T, Hirao K, et al. [Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer]. Gan To Kagaku Ryoho 2003; 30:489-494.
74. Cho H, Konishi K, Tsuburaya A, Kobayashi O, Saijrengi M, Motohashi H, et al. Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1. Gastric Cancer 2003; 6(suppl 1):24-27.
75. Takahashi I, Kakeji Y, Emi Y, Sakurai M, Yonemura Y, Kimura Y, et al. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer 2003; 6(suppl 1):28-33.
76. Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, et al. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer 2003; 6(suppl 1):34-39.
77. Chollet P, Schöffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003; 39:1264-1270.
78. Baba H, Ohtsu A, Sakata Y, Mitachi Y, Sugimachi K, Taguchi T. Late phase II study of S-1 in patients with advanced colorectal cancer in Japan. Proc Am Soc Clin Oncol 1998; 17:1065 (abstr).
79. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000; 83:141-145.
80. Sawada T, Hirakawa K, Shirao A. Confirmatory phase II study and final results of S-1 in patients with metastatic colorectal cancer (CRC) in Japan. Proc Am Soc Clin Oncol 2002; 21:102b (abstr 2223).
81. Van den Brande J, Schöffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003; 88:648-653.
82. Fujii M, Kanzaki J, Satake B, Baba S, Inayama Y. Early phase II study of S-1 in patients with advanced head and neck cancer. Proc Am Soc Clin Oncol 1996; 15:894 (abstr).
83. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Early phase II study of S-1 in patients with advanced head and neck cancer.] Gan To Kagaku Ryoho 1998; 25:1151-1158.
84. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Late phase II study of S-1 in patients with advanced head and neck cancer.] Gan To Kagaku Ryoho 2001; 28:1381-1390.
85. Shirasaka T, Tsukuda M, Inuyama Y, Taguchi T. [New oral anticancer drug, TS-1 (S-1) - from bench to clinic.] Gan To Kagaku Ryoho 2001; 28:855-864.
86. Taguchi T, Horikoshi N, Kinoshita H, Toge T, Takashima S. Early phase II study of S-1 in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1996; 15:151 (abstr).
87. Taguchi T, Morimoto K, Horikoshi N, Takashima S, Toge T, Kimura M, et al. [An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)]. Gan To Kagaku Ryoho 1998; 25:1035-1043.
88. Sano M, Saeki T, Takashima S, Horikoshi N, Miura S, Morimoto K, et al. Late phase II study of S-1 in patients with advanced and/or recurrent breast cancer. Proc Am Soc Clin Oncol 2000; 19:404 (abstr).
89. Furuse K, Kawahara M, Hasegawa K, Kudoh S, Takada M, Sugiura T, et al. Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol 2001; 6:236-241.
90. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001; 85:939-943.
91. Sakai S, Ichinose Y, Yoshimori Y, Nakai Y, Sugiura T, Kawahara M, et al. Phase II trial of S-1 plus cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22:2628 (abstr).
92. Okada S, Okusaka H, Ueno H, Ikeda M, Kuriyama H, Saisho T, et al. A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2002; 21:171a (abstr 682).
93. Hayashi K, Imaizumi T, Uchida K, Kuramochi H, Takasaki K. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1. Oncol Rep 2002; 9:1355-1361.
94. Hayashi K, Imaizumi T, Kuramochi H, Uchida K, Takasaki K. High response rates in patients with pancreatic cancer using the oral fluoropyrimidine S-1. Proc Am Soc Clin Oncol 2003; 22:1042 (abstr).
95. Tahara M, Ohtsu A. [Latest progress on chemotherapy for advanced gastric cancer]. Gan To Kagaku Ryoho 2000; 27:2048-2058.
96. Kinoshita T, Konishi M, Nakagohri T, Inoue K, Oda T, Takahashi S, et al. Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study. Gastric Cancer 2003; 6(suppl 1):40-44.
97. Fujitani K, Tsujinaka T, Hirao M. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding. Hepatogastroenterology 2003; 50:889-892.
98. Ohtsu A, Boku N, Nagashima F, Koizumi W, Tanabe S, Saigenji K, et al. A phase I/II study of S-1 plus cisplatin (CDDP) in patients (pts) with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 2001; 20:165a (abstr 656).
99. Nagashima F, Ohtsu A, Boku N, et al. Japanese nation-wide post marketing survey of S-1 in patients with advanced gastric cancer. Presented at: 4th Int Conf on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Köln, September 2001.
100. Kawai H, Ohtsu A, Boku N, Hamamoto Y, Nagashima F, Muto M, et al. Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. Gastric Cancer 2003; 6(suppl 1):19-23.
101. Suzuki M, Sekiguhi I, Sato I, Shirasaka T. Combined effects of S-1, a new form of oral tegafur, plus modulators on ovarian cancer in nude rats. Chemotherapy 1996; 42:452-458.
102. Kamata T, Hayashi Y, Minatoya G, Michiwa Y, Onishi I, Takeda T, et al. [A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer.] Gan To Kagaku Ryoho 2001; 28:1419-1422.
103. Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer 2003; 6(suppl 1):45-49.
104. Tsujitani S, Fukuda K, Kaibara N. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer. Gastric Cancer 2003; 6(suppl 1):50-57.
105. Saikawa Y, Akasaka Y, Kanai T, Otani Y, Kumai K, Kubota T, et al. Preoperative combination chemotherapy with S-1 and low dose cisplatin against highly advanced gastric carcinoma. Oncol Rep 2003; 10:381-386.
106. Akiba Y, Takaishi H, Saikawa Y, Kubota T, Fujii M, Kitajimi M, et al. High histological response and low toxicity of preoperative chemotherapy with S-1 plus low dose CDDP against stage IV gastric cancer. Proc Am Soc Clin Oncol 2003; 22:1254 (abstr).
107. Tsujitani S, Kondo A, Kaibara N. Sequential chemotherapy with low-dose CDDP/S-1 and CDDP/CPT-11 for advanced gastric cancer. Proc Am Soc Clin Oncol 2003; 22:1358 (abstr).
108. Narahara H, Takiuchi H, Tsujinaka T, Furukawa H, Taguchi T. Phase I study of CPT-11 plus S-1 in patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2002; 21:170a (abstr 677).
109. Komatsu Y, Takeda H, Takei M, Kato T, Tateyama M, Miyagishima T, et al. A phase I and PK study of CPT-S-1 and irinotecan (CPT-11) in patients with advanced gastric ancer (AGC). Proc Am Soc Clin Oncol 2002; 21:171a(abstr 683).
110. Yamashita T, Ichikawa W, Nihei Z, Kojima K, Kawano T, Sugihara K. A phase I study of S-1 and weekly CPT-11 for patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2003; 22:1428 (abstr).
111. Yamada Y, Goto A, Ura T, Arai T, Hamaguchi T, Muro K, et al. Phase I and pharmacokinetic study of S-1 in combination with CPT-11 for advanced gastric cancer. Proc Am Soc Clin Oncol 2003; 22:1314 (abstr).
112. Komatsu Y, Takei M, Takeda H, Kudo M, Kunieda Y, Tateyama M, et al. Phase II study of CPT-11 plus S-1 in patients with advanced gastric cancer for Hokkaido Gastrointestinal Cancer Study Group. Proc Am Soc Clin Oncol 2003; 22:1282 (abstr).
113. Yoshida K, Nishiyama M, Toge T, Hirabayashi M, Takiyama W, Ninomiya M, et al. Combination phase I/II study of S-1 and docetaxel with advanced or recurrent gastric cancer. Proc Am Soc Clin Oncol 2003; 22:1292 (abstr).
114. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
115. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51:15-36.
116. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49:33-64.
117. Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Clin North Am 2002; 82:905-941.
118. Calvert H. Clinical developments with folate-based thymidylate synthase inhibitors. Proc Am Soc Clin Oncol Educational Book 1998; 17:295-299.
119. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
120. Pazdur R. New agents for colorectal cancers: oral fluorinated pyrimidines and oxaliplatin. Proc Am Soc Clin Oncol Educational Book 1998; 17:300-310.
121. Rustum YM, Cao S, Zhang Z. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. Cancer J Sci Am 1998; 4:12-18.
122. Au JL, Sadee W. The pharmacology of ftorafur (R,S-1-(tetrahydro-2- furanyl)-5 fluorouracil). Rec Results Cancer Res 1981; 76:100-114.
123. Au JL, Wu AT, Friedman MA, Sadee W. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep 1979; 63:343-350.
124. Grem J. L. 5-Fluoropyrimidines. In: Chabner BA, Longo DL (editors): Cancer Chemotherapy and Biotherapy, 2nd edn. Philadelphia, PA: Lippincott-Raven; 1996, pp. 149-211.
125. Bajetta E, Carnaghi C, Somma L, Stampino CG. A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori 1996; 82:450-452
126. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K, et al. Angiogenic activity of enzymes. Nature 1994; 368:198.
127. Kono H, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 1983; 31:175-178
128. Ishikawa T, Utoh M, Sawada N, Sekiguchi F, Ishitsuka H. Xeloda (capecitabine): an orally available tumor-selective fluoropyrimidine carbamate. Proc Am Soc Clin Oncol, 1997; 16:208A (abstr).
129. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
130. Cao S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994; 54:1507-1510.
131. Baccanari DP, Davis ST, Knick VC, Spector T. 5-Ethynyluracil: effects on pharmacokinetics and antitumor activity of 5-FU. Proc Natl Acad Sci USA 1993; 90:11064-11068.
132. Khor SP, Lucas S, Shilsy R, Burris H, von Hoff DD, Zhang R, et al. A phase I/pharmacokinetic study of 5-ethynluracil plus 5-fluorouracil in cancer patients with solid tumors. Proc Am Ass Cancer Res 1995; 36:1439 (abstr).
133. Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, et al. Pharmacokinetic, oral bioavalibility and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14:3085-3096.
134. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22:333-338.
135. Fujii S, Fukushima M, Shimamoto Y, Ohshimo H, Imaoka T, Shirasaka T. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn J Cancer Res 1989; 80:173-181.
136. Miyauchi S, Imaoka T, Utsunomiya T, Hayashi K, Kubo M, Kawaguchi T, Matsui Y. Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels. Jpn J Cancer Res 1994, 85:665-668.
137. Shirasaki T, Fukushima M, Shimamoto Y, Kimura Y, Ohshimo H, Imakoka T, et al. Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn J Cancer Chemother 1990; 17:1051-1058.
138. Shirasaka T, Fujita F, Fujita M, Fukushima M, Taguchi T, Fujii S. Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted into nude mice. Jpn J Cancer Chemother 1990; 17:1871-1876.
139. Yoneda K, Yamamoto T, Ueta E, Osaki T. The inhibitory action of BOF-A2, a 5-fluorouracil derivative, on squamous cell carcinoma. Cancer Lett 1999; 137:17-25.
140. Fujita F, Fujita M, Fujita M, Sakamoto Y. [Combination chemotherapy of BOF-A2, a new 5-FU derivative, with various anticancer agents against human cancer xenografts in nude mice]. Gan To Kagaku Ryoho 1994; 21:1619-1625.
141. Fujita F, Fujita M, Sakamoto Y, Taguchi T. [Antitumor activity of combination treatment of BOF-A2 with CDDP against human lung cancers xenografted in nude mice]. Gan To Kagaku Ryoho 1993; 20:215-221.
142. Suzuoki Y, Saito T, Taguchi T, Ohta K, Furue H, Niitani H, et al. Phase I clinical study of BOF-A2, a new 5-fluorouracil derivative. Proc Jpn Cancer Assoc 1990; 49:374.
143. Sasaki T. [New anti-cancer drugs for gastrointestinal cancers]. Gan To Kagaku Ryoho 1997; 24:1925-1931.
144. Nemunaitis J, Eager R, Twaddell T, Corey A, Sekar K, Tkaczuk K, et al. Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. J Clin Oncol 2000; 18:3423-3434.
145. Hasegawa K, Kimura K, Saito T, Taguchi T, Niitani H, Furue H, et al. Early Phase II trial of BOF-A2, a new 5-FU derivative. J Jpn Soc Cancer Ther 25:2151-1990.
146. Sugimachi K, Maehara Y. A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer. Surg Today 2000; 30:1067-1072.
147. Nakai Y, Furuse K, Ohta M, Yamaguchi Y, Fuji M, Asakawa M, et al. Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. Acta Oncol 1994; 33:523-526.
148. Kawabe S, Takiuchi H, Gotoh M, Ohta S, Katsu KI. Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression in inoperable gastric cancer: a predictive marker of benefit to decide the regimen. Proc Am Soc Clin Oncol 2003; 22:1436 (abstr).
149. Usuki H, Ishimura K, Yachida S, Hagiike M, Okano K, Izuishi K, et al. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effects of DPD inhibitory fluoropyrimidines. Gastric Cancer 2003; 6(suppl 1):66-70.
150. Terashima M, Fujiwara H, Takagane A, Abe K, Irinoda T, Nakaya T, et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer 2003; 6(suppl 1):71-81.
151. Yoshida K, Tanabe K, Ueno H, Ohta K, Hihata J, Toge T, et al. Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study. Gastric Cancer 2003; 6(suppl 1):82-89.